Attention: If you are over 30 and have been diagnosed with hormone-receptor-positive breast cancer — or told you are at high risk — the fear of recurrence or a future diagnosis can keep you awake at night. As a doctor practising in Australia, I see this every day. The good news is that tamoxifen is a proven, affordable, PBS-listed medicine that has been protecting Australian women for decades. It is not experimental. It is a trusted oral tablet that blocks oestrogen in breast cells and significantly reduces the chance of hormone-receptor-positive breast cancer returning or developing in the first place.
Tamoxifen is a selective oestrogen receptor modulator (SERM). It works by occupying oestrogen receptors on breast cells, preventing oestrogen from stimulating cancer growth. In Australia, tamoxifen is available as 10 mg and 20 mg tablets and is subsidised through the Pharmaceutical Benefits Scheme (PBS) for eligible patients. This means you pay a reduced co-payment rather than the full private price, making it one of the most cost-effective hormone therapies available.
Many patients ask me, "Will tamoxifen actually work for me?" This is a critical question, and the answer is closely linked to a liver enzyme called CYP2D6.
Tamoxifen is a pro-drug. Your body must convert it into endoxifen, the active metabolite that does most of the anti-cancer work. This conversion is carried out mainly by the CYP2D6 enzyme in your liver. If you have a genetic variation that makes you a poor metaboliser, you may produce much less endoxifen, and tamoxifen may be less effective for you. This is a real concern for some patients, especially those taking certain antidepressants such as paroxetine or fluoxetine, which strongly inhibit CYP2D6.
In Australia, CYP2D6 genotyping is available through specialised pathology laboratories. It is not routinely ordered for every patient, but it may be considered if there is concern about reduced efficacy or significant drug interactions. Always discuss this with your oncologist or prescribing doctor.
| Metaboliser Status | What It Means | Australian Clinical Approach |
|---|---|---|
| Extensive / normal metaboliser | Produces adequate endoxifen; tamoxifen likely effective. | Standard tamoxifen dose; no change needed. |
| Intermediate metaboliser | Reduced enzyme activity; endoxifen levels may be lower. | Discuss with specialist; may adjust dose or consider alternative if clinically indicated. |
| Poor metaboliser | Very low endoxifen; tamoxifen may be less effective. | Consider alternative endocrine therapy (e.g., aromatase inhibitor if postmenopausal) or avoid strong CYP2D6 inhibitors. |
Yes. For Australian women at high risk of breast cancer — such as those with a strong family history, a known BRCA1 or BRCA2 mutation, previous atypical ductal hyperplasia, or lobular carcinoma in situ — tamoxifen can be prescribed as chemoprevention. International studies and Australian guidelines support discussing tamoxifen for high-risk women. In these women, tamoxifen can reduce the risk of developing invasive breast cancer by approximately 30–40%. This is one of the most powerful tools we have to prevent a future diagnosis.
In Australia, using tamoxifen for prevention may require an authority prescription and a detailed discussion with a breast specialist or oncologist. The PBS does subsidise tamoxifen for certain high-risk prevention indications, but eligibility criteria apply. If you believe you are high risk, ask your GP for a referral to a specialist.
This is a common worry, particularly if you are lactose intolerant. Many tamoxifen brands available in Australia do contain lactose monohydrate as an inactive filler. However, the amount per tablet is very small — usually less than 100 mg — and most people with lactose intolerance can take it without symptoms. If you have severe lactose intolerance or galactosaemia, ask your pharmacist to check the specific brand's excipient list or provide the Consumer Medicines Information (CMI). Some brands may have different fillers, so switching brands can sometimes help.
Tamoxifen is not routinely used in children in Australia. There is no established role for tamoxifen in children with breast cancer, which is extraordinarily rare, or for prevention. In rare paediatric conditions such as McCune-Albright syndrome or severe pubertal gynaecomastia, tamoxifen has been used under specialist paediatric endocrinology, but this is off-label and highly specialised. If you are asking about a child, please consult a paediatric specialist — do not use adult dosing.
One of the biggest barriers to starting tamoxifen is fear of side effects. Let me address the most pressing safety concerns directly.
Surveillance on tamoxifen is designed to catch problems early and keep you safe. While individual plans vary, the following table reflects common Australian practice aligned with eviQ and specialist guidelines.
| Monitoring Item | Frequency | Purpose |
|---|---|---|
| Clinical review with GP or oncologist | Every 6 months for the first 2 years, then annually | Check side effects, adherence, and overall health |
| Breast imaging (mammogram or ultrasound) | Annually, or as advised by your specialist | Detect any new breast changes early |
| Gynaecological review (if uterus intact) | Annually; report any abnormal vaginal bleeding immediately | Monitor for endometrial changes; tamoxifen slightly increases endometrial cancer risk |
| Endometrial assessment (ultrasound or biopsy) | Only if symptoms such as bleeding or pelvic pain occur | Routine ultrasound without symptoms is not recommended in most Australian guidelines |
| Liver function tests | Baseline and as clinically indicated | Monitor for rare liver effects |
| Bone density review | Discuss with your doctor, especially if postmenopausal | Tamoxifen can be bone-protective in postmenopausal women; premenopausal women may need monitoring |
Important: Swelling in one leg, especially with pain, warmth, redness, or tenderness in the calf, could be a sign of a deep vein thrombosis (DVT). Tamoxifen increases the risk of blood clots. If you develop sudden leg swelling, shortness of breath, chest pain, or cough up blood, stop tamoxifen and seek urgent medical attention immediately. Call 000 or go to your nearest emergency department. Your doctor may arrange a Doppler ultrasound and may temporarily stop tamoxifen or switch you to another therapy.
Swelling in both legs could be fluid retention, which is less dangerous but still needs review. Contact your GP or oncologist for assessment.
Stop tamoxifen and call 000 or go to an emergency department if you develop:
Anaphylaxis is rare but serious. Do not take another dose until you have been assessed.
If you are interested in accessing tamoxifen clinical trials or newer endocrine therapies, Australia has excellent research infrastructure. Here is how to find them:
Tamoxifen remains one of the safest, most affordable, and most effective medications for hormone-receptor-positive breast cancer and high-risk prevention. By understanding how it works, monitoring for side effects, and accessing Australian support systems, you can use it with confidence.
Do not let fear of side effects stop you from accessing a medicine that could save your life. Speak to your doctor today about whether tamoxifen is right for you.
Disclaimer: This article is for educational purposes and reflects a doctor's perspective. It does not replace individual medical advice. Always consult your own healthcare provider before starting, stopping, or changing any medication.
